- Home
- ZS vs BIIB Comparison
ZS vs BIIB Comparison
Compare ZS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZS
- BIIB
- Stock Information
- Founded
- ZS 2007
- BIIB 1978
- Country
- ZS United States
- BIIB United States
- Employees
- ZS N/A
- BIIB N/A
- Industry
- ZS EDP Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ZS Technology
- BIIB Health Care
- Exchange
- ZS Nasdaq
- BIIB Nasdaq
- Market Cap
- ZS 31.7B
- BIIB 25.1B
- IPO Year
- ZS 2018
- BIIB 1991
- Fundamental
- Price
- ZS $187.63
- BIIB $149.90
- Analyst Decision
- ZS Buy
- BIIB Buy
- Analyst Count
- ZS 35
- BIIB 26
- Target Price
- ZS $226.21
- BIIB $248.00
- AVG Volume (30 Days)
- ZS 2.5M
- BIIB 1.5M
- Earning Date
- ZS 12-02-2024
- BIIB 02-11-2025
- Dividend Yield
- ZS N/A
- BIIB N/A
- EPS Growth
- ZS N/A
- BIIB 10.05
- EPS
- ZS N/A
- BIIB 11.06
- Revenue
- ZS $2,299,023,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- ZS $25.34
- BIIB N/A
- Revenue Next Year
- ZS $20.57
- BIIB N/A
- P/E Ratio
- ZS N/A
- BIIB $13.55
- Revenue Growth
- ZS 30.77
- BIIB N/A
- 52 Week Low
- ZS $153.45
- BIIB $145.07
- 52 Week High
- ZS $259.61
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- ZS 41.61
- BIIB 35.04
- Support Level
- ZS $179.11
- BIIB $145.07
- Resistance Level
- ZS $209.39
- BIIB $149.92
- Average True Range (ATR)
- ZS 7.17
- BIIB 3.71
- MACD
- ZS -2.38
- BIIB 0.26
- Stochastic Oscillator
- ZS 22.67
- BIIB 30.65
About ZS Zscaler Inc.
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.